Navigation Links
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
Date:12/4/2008

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data suggest that inhibiting the IL-5R pathway may lead to a targeted approach for treating patients with asthma, supporting continued study of this antibody.

"Asthma can be a very debilitating disease, and despite current therapies, patients are in need of novel treatment options," said Nestor Molfino, M.D., vice president, clinical development, pulmonary disease. "Some asthmatics may show an increased circulation of eosinophils in blood -- a certain type of white blood cell believed to play a critical role in the severity and disease pathway of asthma; therefore administration of this antibody may increase asthma control."

MEDI-563, which was generated using BioWa's POTELLIGENT(TM) Technology platform, has previously been investigated in a Phase 1 open-label dose-escalating study to evaluate the safety and tolerability of a single intravenous infusion in adults with mild-to-moderate asthma. Data from the completed Phase 1 study demonstrated that the antibody was well-tolerated with biologic activity producing substantial and prolonged depletion of blood eosinophils, thus supporting its continued development. Published literature suggests that reduction of eosinophils in sputum was associated with better asthma control and increases in sputum eosinophilia were associated with exacerbations of asthma. The antibody is also currently being evaluated in a double-blind, placebo-controlled Phase 1 study to evaluate the safety and tolerability and effects of the antibody on airway eosinophils in adults with asthma.

About Interleukin-5 Receptor (IL-5R)

Interleukin-5 is a cytokine secreted predominantly
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Announces Zook as President
2. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
5. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
6. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
7. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... 2011 EMG Laboratory ... the American Association of Neuromuscular & Electrodiagnostic Medicine,s ( ... Status. EMG Laboratory has provided advanced testing of ... Merrimack Valley and Cape Cod since 1997. Currently, it ...
... NEW YORK, Aug. 3, 2011 ... research report is available in its ... and Commercial Outlook 2011-2021 - discovering ... http://www.reportlinker.com/p0578545/Biomarkers-Technological-and-Commercial-Outlook-2011-2021---discovering-the-pharma-and-diagnostics-opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ...
... 2011 Informex , the leading meeting ... today announced the introduction of a new conference, ... the Biopharmaceutical Evolution, to be hosted October 5-6th, ... will cover on-trend topics regarding the future of ...
Cached Biology Technology:EMG Laboratory Attains Prestigious National Accreditation for Clinical Excellence in Neuromuscular Diagnosis 2EMG Laboratory Attains Prestigious National Accreditation for Clinical Excellence in Neuromuscular Diagnosis 3Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 2Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 3Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 4Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 5Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 6Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 7Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 8Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 9Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 10Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 11Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 12Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 13Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 14New Conference Offers Solutions for Success in the Growing Biologics Market 2New Conference Offers Solutions for Success in the Growing Biologics Market 3
(Date:10/19/2014)... the last 30 years contributed only marginally to ... time, according to a new study published in ... access is fundamental to development: it brings improvements ... and health," says IIASA researcher Shonali Pachauri, who ... is widely agreed to be an important goal ...
(Date:10/18/2014)... October 2014 Psychological stress and stress-related psychiatric disorders ... diseases, but the molecular mechanisms underlying this ... contribute to the development of targeted preventive ... these devastating diseases. This work is presented ... in Berlin., Now an international group of ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Researchers find why depression and aging linked to increased disease risk 2Whole-exome sequencing shows potential as diagnostic tool 2
... informal electronic waste salvage site in Ghana,s capital Accra ... pollutants over 50 times higher than risk-free levels. ... field are likewise polluted to varying degrees, all neighbours ... is scavenged for valuable metals - especially copper. Schoolchildren ...
... CHESTNUT HILL, Mass. (October 29, 2011) A major public ... thought leaders for a day-long examination of the contributions of ... university and to society. ,Science in the Liberal Arts ... free public symposium sponsored by BC,s Institute for the Liberal ...
... genome has been decoded. Of all the puzzles it contains, ... the blueprint for various proteins, the building blocks of each ... proteins control cell division in a healthy body, for instance? ... incessantly subdivide and control over proteins gets out of hand? ...
Cached Biology News:High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 2High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 3High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 4High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 5Science in the liberal arts university 2Cell cultures from a machine 2
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
... MKK6 (phospho S207) ( Abpromise ... Antigen: Synthetic phosphopeptide derived ... site of Serine 207 (V-D-S P ... ID: 5608 ...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Biology Products: